About This Series
Clostridioides difficile infection (CDI) is the most common healthcare associated infection the United States and the most common cause of mortality in patients with gastroenteritis. Recurrent CDI leads to increased morbidity, mortality, healthcare costs, and decreased quality of life. Treatment of CDI is evolving with a greater emphasis on prevention of recurrence also known as sustained clinical response.
This educational series will explore concepts of epidemiology, pharmacology, immunology, and microbiome science to describe the sequence of events that place patients at high risk for recurrent CDI. Preparation and formulation of cost-effective treatment plans that optimize therapy and provide a rational anti-CDI recurrence treatment strategy and the current and near future therapeutic targets to prevent CDI recurrence will also be highlighted.
Part 1: On-Demand Activity
Strategies for Prevention and Treatment of Recurrent C. difficile Infection
This 1.5-hour interprofessional educational activity will apply concepts of epidemiology, pharmacology, immunology, and microbiome science to describe the sequence of events that place patients at high risk for recurrent Clostridiodes difficile infection (CDI). Treatment strategies will also be explored.
Part 2: Ask the Experts Webinar
This reinforcement activity features pharmacist and physician faculty continuing the discussion from Part 1 and addressing additional questions posed by learners.
Wednesday, April 1, 2020
1:00 – 2:00 p.m. ET
Part 3: Engaging the Experts
Listen to interviews with faculty on key topics via podcast or on the activity website.